CFTR and cystic fibrosis: These compounds were found to overcome the processing defect of the mutant CFTR protein involved in cystic fibrosis, and to be up to 2 orders of magnitude more efficient as CFTR correctors than the clinical candidate miglustat (N-Bu-DNJ, 1, Figure 1).